NV-VERACODE
Black Hat USA Conference (booth #2536) – Veracode, a global leader in application risk management, today announced platform innovations to help organizations uncover, prioritize, and reduce security debt across their growing attack surface. Universal Connector and Application Security Heatmap, the two newest capabilities from Longbow powered by Veracode, allow organizations to quickly connect findings from any source and see the applications that are contributing to the most risk. Together, the Universal Connector and the Application Security Heatmap provide clear, operational insight into assets and issues, allowing remediation actions to be prioritized by quantifiable risk.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240801020287/en/
Figure 1: State of Software Security 2024 Language Snapshot (Graphic: Business Wire)
“The combination of mounting security debt, an expanding attack surface made more vulnerable by generative AI, and an overwhelming volume of security alerts makes it challenging for organizations to know which application risks to prioritize,” said Chris Eng, Chief Research Officer at Veracode. “In fact, our State of Software Security research shows that many organizations are more focused on remediating low-severity flaws than critical flaws. Security leaders need technology that enables them to effectively uncover and manage application risk, and then reduce that risk by focusing on the issues that matter most across their entire attack surface.”
Prioritization of Security Debt: Critical vs Non-critical
In its State of Software Security 2024 Language Snapshot, Veracode revealed the varying prevalence of “critical” and “non-critical” security debt among applications written in different languages. Critical security debt is defined for this report as high-severity flaws that remain unfixed for longer than a year. If exploited, these flaws would put the integrity and availability of organizations at serious risk.
The research found that while most security debt exists in first-party code written by in-house developers, the most critical security debt resides in third-party code (e.g., open-source software imported into the codebase). For example, 80 percent of critical debt in Java apps, and 63 percent in JavaScript apps, is in third-party code. The report also found about 51 percent of critical flaws in Java apps turn into security debt, while only about 45 percent of low to medium flaws progress into security debt.
Eng said, “With the overflowing volume of security flaws, developers are not prioritizing those that present the most risk. While focusing on non-critical flaws may result in some quick fixes, developers should use their limited capacity to work on fixing critical flaws with the highest potential impact on security.”
Putting Visibility and Prioritization First: Universal Connector & Application Security Heatmap
Building on Veracode’s acquisition of Longbow Security in April this year, and the introduction of Longbow’s Repo Risk Visibility and Analysis capability in May, Universal Connector and Application Security Heatmap are designed with developers’ time in mind. The capabilities provide operational oversight to help developers and security teams quickly identify and prioritize the most important fixes for growing security debt across their applications.
Universal Connector allows organizations to quickly access disparate source data they otherwise couldn’t bring into the Longbow platform, meaning they don’t have to wait for a tool-specific connector. The Application Security Heatmap maps the application back to the owner and shows a 90-day risk trend, as well as enabling customization of the risk threshold to meet organizational policy. Application security teams and developers can analyze each application, view the distribution of risk, and implement recommendations for the Best Next Action™ to remediate that risk.
“As organizations seek to find and fix mounting critical security debt, the need for risk-focused visibility and prioritization is clear,” said Derek Maki, Vice President of Product Management at Veracode. “The new capabilities in the Longbow platform provide our customers with a deeper understanding of an organization’s riskiest applications, plus the unique ability to identify the top five most impactful solutions for improvement.”
Enhanced by the Longbow acquisition, Veracode closes the gap between development and security teams, delivering visibility from code repositories to cloud assets and runtime. Longbow also identifies infrastructure-as-code and misconfiguration risk for cloud assets originating from repositories.
The Longbow Universal Connector and Application Security Heatmap are available immediately. For more information, please visit the website or watch the interview with Brian Roche, Veracode Chief Executive Officer, and Derek Maki.
The full State of Software Security 2024 Language Snapshot is available on the Veracode website.
Visitors to the Black Hat USA Conference, August 3-8, 2024, can learn more about Veracode’s platform and these new features by visiting Veracode’s booth #2536 for a demo.
About the State of Software Security Report
The Veracode State of Software Security 2024 report analyzed data from large and small companies, commercial software suppliers, software outsourcers, and open-source projects. The research draws from more than a million (1,007,133) applications across all scan types, 1,553,022 dynamic analysis scans, and 11,429,365 static analysis scans. All those scans produced 96 million raw static findings, 4 million raw dynamic findings, and 12.2 million raw software composition analysis findings.
About Veracode
Veracode is a global leader in Application Risk Management for the AI era. Powered by trillions of lines of code scans and a proprietary AI-assisted remediation engine, the Veracode platform is trusted by organizations worldwide to build and maintain secure software from code creation to cloud deployment. Thousands of the world’s leading development and security teams use Veracode every second of every day to get accurate, actionable visibility of exploitable risk, achieve real-time vulnerability remediation, and reduce their security debt at scale. Veracode is a multi-award-winning company offering capabilities to secure the entire software development life cycle, including Veracode Fix, Static Analysis, Dynamic Analysis, Software Composition Analysis, Container Security, Application Security Posture Management, and Penetration Testing.
Learn more at www.veracode.com, on the Veracode blog, and on LinkedIn and X.
Copyright © 2024 Veracode, Inc. All rights reserved. Veracode is a registered trademark of Veracode, Inc. in the United States and may be registered in certain other jurisdictions. All other product names, brands or logos belong to their respective holders. All other trademarks cited herein are property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240801020287/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer22.12.2025 08:42:00 CET | Press release
Incyte Biosciences Japan G.K. today announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of advanced squamous cell carcinoma of the anal canal (SCAC). "Today's approval marks a significant milestone for patients with advanced anal cancer in Japan – the MHLW’s approval of Zynyz as the first and only first-line treatment for SCAC," said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan G.K. "By offering combination therapy with chemotherapy, Zynyz provides a vital new path forward for patients facing this challenging disease, addressing a significant unmet need in cancer care for patients with SCAC and their families." The approval was based on data from the Phase 3 POD1UM-303/InterAACT2 trial evaluating Zynyz in combination with platinum-based chemotherapy (carboplatin-paclitaxel) in adult patients with metastatic or inoperable
GBC AG Analyst Coverage Report on Mexedia S.p.A. Società Benefit Completed and Published22.12.2025 08:30:00 CET | Press release
Regulatory News: Mexedia S.p.A. Società Benefit (Euronext Growth Paris: ALMEX, ISIN IT0005450819) (“Mexedia” or the “Company”) informs that the analyst coverage report prepared by GBC AG – one of the leading independent financial research firms in Germany –, developed within an issuer-sponsored research framework, has been completed and is now publicly available. The report follows the re-initiation of analyst coverage by GBC AG previously communicated by the Company and is based exclusively on publicly available information. The content, assumptions and conclusions of the report are solely attributable to the analyst. The GBC AG analyst coverage report is available on the Company’s official website at the following address: https://mexedia.com/en/financial-statements-and-reports/ and on the analyst’s website. Daniel Gilcher, Chief Financial Officer of Mexedia S.p.A. Società Benefit, stated: “The completion and publication of the analyst coverage report by GBC AG represents the conclus
Hisense Joins HEVC Advance Patent Pool22.12.2025 03:06:00 CET | Press release
Access Advance LLC, the global leader in video codec patent pool licensing, today announced that Hisense Group Holdings Co., Ltd. has joined the HEVC Advance Patent Pool as a Licensee. Hisense joins the recent additions to the Access Advance patent pools, including Xiaomi, MSI, Transsion, and expanded relationships with Huawei, HP and Sharp. Hisense, headquartered in Qingdao, China, is one of the world's largest television manufacturers, with a global presence spanning Asia, Europe, the Americas, and beyond. The company's products reach consumers in more than 160 countries and regions worldwide. "We are pleased to welcome Hisense to the HEVC Advance Patent Pool," said Peter Moller, CEO of Access Advance. "This agreement is the result of extensive engagement between our teams over a considerable period of time. Hisense's decision to join the pool reflects a recognition that transparent, efficient licensing solutions benefit both innovators and implementers across the video technology ec
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
